Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9BXB7

UPID:
SPT16_HUMAN

ALTERNATIVE NAMES:
Testis development protein NYD-SP12

ALTERNATIVE UPACC:
Q9BXB7; Q0R0N4; Q0R0S0; Q0R0W2; Q0R129; Q0R131; Q0R140; Q0R1B8; Q0R1G5; Q0R1I2; Q0R1J6; Q0R1S4; Q0R202; Q0R280; Q0R2F8; Q0R2N6; Q0R2N7; Q0R2R0; Q0R2R1; Q0R2S3; Q0R2S4; Q0R2S5; Q0R2T4; Q0R2T7; Q0R2U2; Q0R2U8; Q0R2U9; Q0R2V5; Q0R2V7; Q8NE67

BACKGROUND:
The role of Spermatogenesis-associated protein 16 in male reproductive health is critical, as evidenced by its essential functions in spermiogenesis and male fertility. This protein, alternatively named Testis development protein NYD-SP12, is crucial for the proper formation of the sperm acrosome and the normal arrangement of mitochondria in sperm cells, highlighting its importance in the successful fertilization process.

THERAPEUTIC SIGNIFICANCE:
The association of Spermatogenesis-associated protein 16 with Spermatogenic failure 6, an infertility disorder stemming from spermatogenesis anomalies, underscores the therapeutic potential of targeting this protein. Exploring the functions and mechanisms of SPATA16 offers promising avenues for developing treatments for male infertility caused by acrosome malformation and other spermatogenic irregularities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.